Viking Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.08.18	OBLN Gaining Weight, CHFS On Track, EIDX On Watch, VKTX Up 178% YTD (RTTNews)
10.08.18	SPRO To Report Data In Q3, ITRM Takes Steady And SURE Steps, PBYI On Watch (RTTNews)
20.06.18	MassRoots Launches Revamped Dispensary Portal, Capable of Serving 2,400+ Licensed Dispensaries in Key Cannabis Markets (PR Newswire)
06.06.18	BIIB's Alzheimer's Drug Scores Well, EXAS Heads Higher, VXRT Down But Not Out (RTTNews)
05.06.18	Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease (PR Newswire)
01.06.18	NASH Data Drives MDGL To The Moon, VKTX Turns Head, FDA Nod For KTOV (RTTNews)
17.05.18	EBIO Gets New Name, Time To Check CHEK, ABAX Snapped Up, GNPX Up 34% In 2 Days (RTTNews)
09.05.18	Viking Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update (PR Newswire)
07.05.18	Recursion Pharmaceuticals Receives Grant to Leverage AI-Enabled Discovery Platform in Infectious Disease (PR Newswire)
02.05.18	Viking Therapeutics to Report Financial Results for First Quarter 2018 on May 9, 2018 (PR Newswire)
07.03.18	Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update (PR Newswire)
06.03.18	Viking Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
28.02.18	Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018 (PR Newswire)
07.02.18	Viking Therapeutics to Present at 2018 BIO CEO & Investor Conference (PR Newswire)
07.02.18	GILD's Sales Wane, SGMO Safe With CHAMPIONS, All's Not Well With Veterinarians? (RTTNews)
01.02.18	Strategikon Advances Planning and Financial Management for Life Sciences with Launch of Clinical Maestro™ (PR Newswire)
16.01.18	The Race To Find A Treatment For NASH (RTTNews)
02.01.18	Viking Therapeutics to Present at Biotech Showcase 2018 (PR Newswire)
11.12.17	Viking Therapeutics Announces Closing of Public Offering of Common Stock (PR Newswire)
05.12.17	Viking Therapeutics Announces Proposed Public Offering of Common Stock (PR Newswire)
29.11.17	EARS Pinched By HEALOS Data, EGLT Does It Again, JAVELIN Gastric 300 Misses Mark (RTTNews)
28.11.17	Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture (PR Newswire)
08.11.17	Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
01.11.17	Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 (PR Newswire)
24.10.17	Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver... (PR Newswire)
23.10.17	Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association (PR Newswire)
04.10.17	Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) (PR Newswire)
29.09.17	Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital (PR Newswire)
25.09.17	Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings (PR Newswire)
11.09.17	Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) (PR Newswire)
07.09.17	Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of... (PR Newswire)
05.09.17	Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference (PR Newswire)
09.08.17	Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
02.08.17	Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017 (PR Newswire)
13.07.17	NVS Gets Thumbs Up, Two Biosimilar Candidates To Face FDA Panel, VKTX On Track (RTTNews)
12.07.17	Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture (PR Newswire)
14.06.17	Viking Therapeutics Announces $4.3 Million Registered Direct Offering (PR Newswire)
06.06.17	Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) (PR Newswire)
03.05.17	Viking Therapeutics to Report Financial Results for First Quarter 2017 After Market Close on May 10, 2017 (PR Newswire)
28.03.17	Viking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference (PR Newswire)
22.03.17	FDA Nod For Parkinson's Drug, ABIO Awaits Data In Q3, Busy Year Ahead For VKTX (RTTNews)
21.03.17	Viking Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update (PR Newswire)
02.03.17	Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2016 After Market Close on March 21, 2017 (PR Newswire)
28.02.17	Viking Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
14.02.17	Viking Therapeutics and PoC Capital Enter Agreement to Fund Clinical Development of VK2809 in Glycogen Storage Disease Ia (GSD Ia) (PR Newswire)
09.02.17	Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) (PR Newswire)
07.02.17	Viking Therapeutics to Present at 2017 BIO CEO & Investor Conference (PR Newswire)
10.01.17	Gainers & Losers Of The Day: DFFN, ETRM, GNVC, EGRX, ADHD... (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	27.07	1.35 %	K V
Zurich Insur Gr	538.60	1.05 %	K V
Swiss Re	129.80	1.01 %	K V
Swiss Life Hldg	694.40	0.87 %	K V
Holcim	86.84	0.86 %	K V
Lonza Grp	532.40	0.26 %	K V
Alcon	76.08	0.08 %	K V
Sika	213.00	-0.09 %	K V
Nestle	73.88	-0.14 %	K V
Geberit	512.00	-0.43 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Viking Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten